The success of the Human Genome Project and the spectacular development of broad genomics tools have catalyzed a new era in both medicine and nutrition. The terms pharmacogenomics and nutrigenomics are relatively new. Both have grown out of their genetic forbears as large-scale genomics technologies have been developed in the last decade. The aim of both disciplines is to individualize or personalize medicine and food and nutrition, and ultimately health, by tailoring the drug or the food to the individual genotype. This review article provides an overview of synergies and differences between these two potentially powerful science areas. Individual genetic variation is the common factor on which both pharmacogenomics and nutrigenomics are based. Each human is genetically (including epigenetics) unique and phenotypically distinct. One of the expectations of both technologies is that a wide range of gene variants and related single-nucleotide polymorphism will be identified as to their importance in health status, validated and incorporated into genotype based strategies for the optimization of health and the prevention of disease. Pharmacogenomics requires rigorous genomic testing that will be regulated and analyzed by professionals and acted on by medical practitioners. As further information is obtained on the importance of the interaction of food and the human genotype in disease prevention and health, pharmacogenomics can provide an opportunity driver for nutrigenomics. As we move from disease treatment to disease prevention, the two disciplines will become more closely aligned.
Introduction
The success of the Human Genome Project and the powerful tools of molecular biology have ushered in a new era in both medicine and nutrition. The pharmaceutical industry expects to leverage sequence data from the Human Genome Project to develop new drugs based on knowledge of drug targets, taking into account variation in the genetic makeup of individuals. Likewise, the food industry now has an opportunity to position food and nutritional bioactives to promote health and prevent disease based on the genetic makeup of the individual consumer.
The term pharmacogenomics (Motulsky, 2002; Steele, 2005; Eichelbaum et al., 2006; Kalow, 2006 ) is relatively new, being first found in the medical literature in the late 1990s. The related term pharmacogenetics was used in the 1950s (Motulsky, 2002) . This early use of the concept is not surprising as it was observed from the start that there is a genetic basis to the differences in the way people respond to drugs. A recent example of a pharmacogenetics medicine is the targeting of BiDil (Taylor et al., 2004) , used for treatment of heart failure, towards black African Americans, although in this case the use of race as a surrogate for genetics is debatable. Genetic variation within and between phenotypically identified populations is relevant to the provision of genetic services and population screening. For example, social group membership can be used clinically as a surrogate for a high risk of a particular genetic variation in the case of people of Ashkenazi Jewish descent, a population with a high familial risk of breast cancer. However, in general, in such screening programmes, treatment on the basis of selfidentification is unlikely to be an effective strategy (Bamshad et al., 2004; Duster, 2005) . In addition, this kind of race and ethnicity classification for medical treatment can lead to discrimination (Richards, 2006) . Pharmacogenomics can be described as an approach to pharmacology that takes into account the genotype of the patient (Motulsky, 2002; Guo et al., 2005; Steele, 2005; Eichelbaum et al., 2006; Kalow, 2006; Phillips and Van Bebber, 2006) . It uses genomic techniques to study drug functionality and discover new drug targets, genetically based high throughput screens to discover new drugs and large-scale genotyping to characterize and analyze the research and treatment populations. Thus, pharmacogenomics uses genotyping to screen populations in order to determine which drugs would work best in human subpopulations in curing or preventing a disease, as well as using various genomic technologies (e.g. gene expression) to understand how the drug is interacting with the genotype. The older term pharmacogenetics differs from pharmacogenomics only in the technologies used and in the breadth of scope of the genes studied.
Nutrigenomics or nutritional genomics (Muller and Kersten, 2003; Trayhurn, 2003; Kaput and Rodriguez, 2004; Labadarios and Meguid, 2004; Ordovas and Mooser, 2004; van Ommen, 2004; Corthesy-Theulaz et al., 2005; Kauwell, 2005; Mutch et al., 2005; Ferguson, 2006; Ordovas, 2006) appears to be a 21st century term, with few references before the year 2000, although the term nutritional genomics was used in 1999 to refer to using plant genomics to improve the nutritional quality of plants (Della Penna, 1999) . Of course, nutritional genetics, the study of the interaction of nutrition with human genotypes, is a much older term (Ordovas and Mooser, 2004) . Nutrigenomics is an approach to nutrition and human health that takes into account and studies the effect of genetic differences in human response to foods. It also uses technologies from genomics and other related areas to study how food has an impact on gene expression, biochemistry, metabolism and promotion of health (Elliott and Ong, 2002; Stover, 2006) . The use of -omics research to analyze the influence of nutrients on human health is thus based on two observations: (1) the nutritional environment modifies the expression of genes, and (2) depending upon the genotype of an individual, the metabolism of nutrients may vary and ultimately result in a different health status (Corthesy-Theulaz et al., 2005) . Thus, nutrigenomics treats food as a major environmental factor in the geneticsenvironment interaction. In parallel with the pharmacogenetics/-genomics split, the extension from nutritional genetics to nutrigenomics thus lies in the use of genomics technologies. Like pharmacogenomics, nutrigenomics also includes the study of the effect of dietary compounds on gene expression as a tool to understand how a nutrigenomic food acts on a particular genotype.
Both pharmacogenomics and nutrigenomics have grown out of their genetic forbears as large-scale genomics technologies have been developed in the last decade (Blum et al., 2006) . The aim of both disciplines is to individualize or personalize medicine and food and nutrition, and ultimately health, by tailoring the drug or the food to the individual genotype. This review article provides an overview of synergies and differences between these two potentially powerful science areas. Our purpose is to show that an individual's genome is ever important in the response to any biologically active substance, such as drugs and nutrients, and that both fields will benefit greatly by understanding the other areas.
Background to individualized medicine and food
Inter-individual variation in drug response among patients is well known and poses a serious problem in medicine. There is a need for rapid and simple methods to discriminate between patients on the basis of their response to a drug. There are no biomarkers at present that can predict which group of patients will or will not respond positively and which will experience adverse reactions for the same medication and dose (Shastry, 2006) . Physicians have to optimize a dosage regimen for an individual patient by a trial-and-error method. This kind of approach may cause adverse drug reactions in some patients. In more than two million cases annually in the US, adverse reactions, including 100 000 deaths (Lazarou et al., 1998; Daniel et al., 2006) have been reported to occur. Similarly, according to a German study, about 6% of adverse drug reactions are attributed to new hospital admissions (Dormann et al., 2004) . This inter-individual variability in drug response could be because of multiple factors such as disease determinants, environmental factors and genetic based variability in drug target response (pharmacodynamic response) and metabolism or idiosyncratic responses. These factors affect drug absorption, distribution, action, metabolism and excretion and have a strong genotype basis (Zheng et al., 2004 ). An understanding of the variability in efficacy and toxicity of the same doses of medications in the human population, therefore, may provide safer and more efficient drug therapy.
It is now clear that nutrients also effect metabolism by exerting their effects at various genetic levels of biological complexity, such as gene transcription, RNA processing, mRNA stability and post-translational modifications (Young, 2002) as well as their direct effects on cell metabolism. Nutritional requirements vary between different physiological groups, including age and gender and also among apparently similar individuals. Various genetic polymorphisms of importance to nutrition have been identified, for example folate metabolism, iron homeostasis, bone health, lipid metabolism, immune function, phenylketonuria and gut inflammation (Baudin, 2000; Stewart and Ralston, 2000; Ye and Kwiterovich, 2000; Mathew, 2001; Moyers and Bailey, 2001) . Foods that are known to cause specific adverse reactions in some genotypes are also well documented, and include gluten in Celiac disease, which is partially linked to HLA DQ2 and DQ8 (Evans et al., 2001) , and lactose intolerance, but the specific genetic defect that underlies the intolerance is often unknown. As more such links between polymorphisms and disease conditions are characterized, and genotype information on individuals is accumulated, the scope for targeting dietary information and recommendations to specific subpopulations based on genotype will increase.
Pharmacogenomics and personalized drug therapy
The science of pharmacogenomics, which aims to define the gene-based determinants of drug efficacy, has evolved over the past 50 years. At present, the best recognized and completely developed examples of genetic polymorphisms that alter drug response in humans are monogenic (single gene) traits that affect drug metabolizing enzymes, drug transporters and drug targets. One such example is that of thiopurine S-methyltransferase (TPMT) and its influence on the thiopurine drugs mercaptopurine and azathiopurine in patients who inherit nonfunctional TPMT alleles (Evans et al., 2001) . Other examples are the inter-individual differences in response to the antihypertensive drug debrisoquine and in the metabolism of the oxytocic drug sparteine, which led to family studies revealing that the pharmacodynamic effects of these drugs are inherited .
Pharmacogenomics may enhance drug discovery and development by allowing genotype-based subpopulationspecific drug development. An example of major importance will be the use of pharmacogenomics to identify genetic polymorphisms that predispose patients to adverse drug effects. Although these may occur in only a small subset of the people treated with a new medication, they are sufficiently toxic to jeopardize further development of the drug for all patients (Kirchheiner et al., 2005; Phillips and Van Bebber, 2005) .
The hope at the outset is that no such toxicities would emerge for new agents under development. Should severe toxicity occur in a very small percentage of patients who could be prospectively identified based on genotype, then an otherwise efficacious new drug might be 'saved' from abandonment during development, or from withdrawal after approval and widespread use. For example, patients at high risk of abacavir hypersensitivity can be identified on the basis of their HLA-B genotypes (Martin et al., 2005) , but it remains unclear whether prospective screening of HLA genotypes is cost-effective with current technology. With the statins (Schmitz and Langmann, 2006) , severe adverse side effects can occur in a minority of patients. Although relevant candidate genes for predicting adverse effects of lipid-lowering drugs, including the statins, have been identified, no reports have yet been made analyzing genetic variants in the genes related to clinical complications. Presumably, this will be the added benefit of pharmacogenomics in the future, in which, as well as targeting appropriate genotypes for drug effect, those with genotypes associated with adverse effects can be identified and alternative treatments selected. It may also mean that drugs with adverse effects in only a proportion of patients may be allowed on the market. One could speculate that this may be the case with the COX 2 inhibitors . More life-threatening toxicities would probably justify the merit of such testing with new medications that have unique pharmacological properties.
The integration of sophisticated genomic tests (e.g., highthroughput sequencing, single-nucleotide polymorphism (SNP) chips, DNA and protein microarrays, and bioinformatics) with extensive phenotypic characterization of uniformly treated patients is essential if we are to define the inherited nature of most drug effects and the identification of drugs that are effective in genetically defined sub populations. A recent example is seen in the use of microarrays to characterize tumors on the basis of their activated oncogenic pathway and to associate this with therapeutic agents (Bild et al., 2006) .
Nutrigenomics and personalized nutrition
Like pharmacogenomics, nutrigenomics also offers the promise of personalizing nutrition to the genotype of the consumer, based on a knowledge of variations in the genes of nutrient metabolism and in downstream genes and proteins that interact with nutrients (nutrient targets) (Mutch et al., 2005) . Although both fields of endeavor are in their infancy, there are a number of new nutritional bioactives that offer glimpses of opportunities to come. Nutrigenomics could provide a framework for the development of genotypedependent novel foods that will promote health and prevent and help manage chronic diseases. For example, phenylalanine-restricted tyrosine-supplemented diets and galactosefree diets are prescribed for the nutritional treatment of type 1 phenylketonuria and galactosemia (galactose-1-phosphate uridyltranferase deficiency), respectively, based on routine genetic tests (Chen, 2001; Longo, 2001) . In these cases, the relevant genes encode proteins directly involved in the metabolism of the nutrients. It is important to note that not all genes that are critical to clinical outcome are directly involved in the pathogenesis of the disease or nutritional benefit. For example, polymorphisms in apolipoprotein E (APO E4) modify the clinical effectiveness of Cognex, which inhibits acetylcholine breakdown in Alzheimer's patients (Poirier et al., 1995) , and also the potential dietary benefits of vitamin E in Alzheimer's disease (Morris et al., 2002) . The study has shown that vitamin E from food may be associated with a reduced risk of Alzheimer's disease, but this association was observed only among individuals without the APO E4 allele.
Nutrient/diet-gene interactions may also explain why some individuals respond more favorably to dietary interventions than others. For example, blood pressure is controlled in part by angiotensin, a vasoconstrictor. An SNP in the gene that encodes the precursor form of this polypeptide, angiotensinogen (ANG), results in a glycine to arginine substitution (G6A) in the gene. The AA genotype for the ANG G À 6A polymorphism has been associated with higher levels of circulating ANG and hypertension (Svetkey et al., 2001) . Interestingly, the results of a sub-study of subjects who participated in the Dietary Approaches to Stop Hypertension (DASH) trial revealed that subjects with the AA genotype were more responsive to the DASH diet than those with the GG genotype (Svetkey et al., 2001) .
Oxidative stress and genetic factors are potent determinants of proinflammatory cytokine production (Grimble, 2002) . One method of reducing inflammatory stress would be to feed nutrients that either suppress proinflammatory cytokine production (e.g. fish oil) (Endres et al., 1989) or act as antioxidants (e.g. vitamin E) (Mol et al., 1997) . At present it is not known whether antioxidants interact with gene variants associated with oxidative stress and inflammation in the same way as anti-inflammatory nutrients, for example n-3 polyunsaturated fatty acid. Proteomic studies have shown a link of iNOS and SOD with the NRAMP1 gene (Kovarova et al., 2001 ). Thus, the high level of oxidant molecules that enhances pro-inflammatory cytokine production is owing to the influence of variations in the NRAMP1 gene. Specific ketogenic diets are already used for the treatment of patients with intractable epilepsy. Balanced diets with essential fatty acids are paramount as the background diet for patients with chronic inflammatory diseases, such as arthritis, asthma, ulcerative colitis, lupus, etc. (Simopoulos, 2002) . As our understanding of the human genome progresses, we can envisage genotype/food interactions being discovered in other areas of health and disease such as athlete training, mood and depression and coping with the aging processes. Thus, the benefits associated with personalized nutrition will include those linked to our state of health and disease prevention and amelioration of many of the 'lifestyle' diseases. On the other hand, personalized drug prescription, by the very nature of the process, is mainly applicable, with a few exceptions, to the treatment of disease or at least the prevention of further deterioration (e.g. osteoporosis).
Relationship between food and drugs
Humans evolved in the presence of a wide variety of different foods, and human metabolism is well adapted to the great variety of foods derived from compounds found in nature. Man-made pharmaceuticals are a modern invention in terms of human evolutionary history. However, one aspect of human physiology is suited to the metabolism of both food chemicals and pharmaceuticals, namely the detoxification mechanisms predominantly carried out by the liver. These detoxification mechanisms are mainly aimed at plant derived xenobiotics (Liska, 1998) , but many drugs are also metabolized by the same systems. This may reflect the number of drugs that are derived from natural compounds (Chin et al., 2006) .
Prescription drugs may interfere with nutrient absorption, digestion, metabolism, utilization or excretion. Similarly, both nutritional status and diet can affect the action of drugs by altering their metabolism and function, and also importantly, various dietary components can have pharmacological activity under certain circumstances (Schmidt and Dalhoff, 2002; Lila and Raskin, 2005) . A well publicized example of drug/nutrient interaction is grapefruit, which can interact with several drugs such as amiodarone, buspirone, carbamazepine, cyclosporine and nifedipine. There can also be dangerous interactions between monoamine oxidase inhibitors such as phenelcypromine, tranylcypromine and isocarboxazid with tyramine, a substance found in some foods and beverages (e.g. all aged and mature cheeses, fermented soy products and air-dried sausages) (Marcason, 2005) . Adverse interaction between blood-thinning warfarin and vitamin K is also reported (Camilo et al., 1998) . High doses of aluminum or magnesium hydroxide antacids can cause phosphate depletion, leading to muscle weakness, anorexia and even congestive heart failure. Thiazide and furosemide diuretics can cause sodium, potassium and magnesium depletion, resulting in anorexia and muscle weakness (Knauf et al., 2006) . Commonly used folate antagonists include methotrexate, a cancer-chemotherapeutic agent; triamterene, a diuretic; trimethoprim, an antibacterial agent; phenytoin, an anticonvulsant; and sulphasalazine, an anti-inflammatory agent (Nozaki et al., 2004) . Sulphasalazine and phenytoin are competitive inhibitors of folate transport in addition to being folate antagonists. Folate deficiency can lead to weight loss and anorexia. Penicillamine induces zinc depletion, which may cause a loss of taste acuity and possibly decreased food intake (Floersheim et al., 1984) . Alcohol abuse also commonly results in deficiencies of thiamin, folate, vitamin B 6 , vitamin A and zinc (Bowden et al., 1994) . Nutrients are sometimes used in unusually high doses for their pharmacologic effect. Niacin, for example, is used pharmacologically to reduce blood cholesterol levels (Morgan et al., 2004) . Retinoid derivatives of vitamin A have been used successfully to treat severe acne and other conditions (Thielitz et al., 2006) . None of these examples is known to include a genotype component, but individuals who are born with deficiencies in the genes need to produce key functional enzymes, and may require amounts of certain nutrients greatly in excess of those required by most people. Such inborn metabolic errors have been identified for enzymes necessary for absorption, metabolism or storage of nearly all of the vitamins. Thus, as the relationships between foods and drugs become more fully understood, so will the linkages between pharmacogenomics and nutrigenomics.
Shifting the paradigm from treatment to prevention in nutrition and pharmacology
The concept of the link between nutrition and health is best appreciated if we move from the biomedical approach of Pharmacogenomics and nutrigenomics D Ghosh et al treating disease, and awareness of maintaining health. An awareness that multiple minor changes in metabolism and its biochemical regulation contribute to the onset of chronic nutrition-related disorders emphasizes the importance of nutrition in health maintenance. Examples where nutrition can promote health, and not merely treat disease, include obesity, diabetes type 2, cardio vascular disease (CVD), osteoporosis and chronic inflammatory syndromes, all of which show genetic based differences in susceptibility (Child, 1988) . It is absolutely imperative that human nutritional intervention studies take advantage of nutrigenomics developments by moving on from focussing on disease or damage, and apply these genetic based nutrigenomics tools toward health promotion and the prevention of disease. Knowledge of the genotype will allow selection of health promoting food and extracts for individuals. Fortified foods, functional foods, and nutraceuticals are bioactive natural compounds that have health promoting or disease preventing properties. For example, the natural angiotensin converting enzyme (ACE) inhibitor activity in milk peptides may be used in certain genotypes to control hypertension (FitzGerald et al., 2004) instead of using synthetically produced ACE inhibitor drugs, whose activity depends on particular gene polymorphisms. Obesity is one area where the application of both genomic and nutritional approaches has already been highly successful (Defeat Diabetes Association, 2003) . Another example is colon cancer, where an estimated 60% of the cancers are related to nutrition (Stierum et al., 2001) . It may be more effective in the long run to investigate the maintenance of optimal gut health instead of the application of nutrition against the recurrences of adenomas after surgical intervention. Likewise, prevention of chronic metabolic stress through optimal nutrition may be more effective than dietary therapy of atherosclerosis with antioxidant vitamins.
Pharmaceuticals are available that can be viewed as aiding in disease prevention/health maintenance. For example, the 3-hydroxymethlglutaryl coenzyme A reductase inhibitors or statins are used to prevent CVD by lowering cholesterol (Shepherd et al., 1995) . Similarly, the consumption of plant sterol functional foods as part of the diet has been reported to have similar overall effects in cholesterol reduction (Goldberg et al., 2006) . There is evidence that subsets of individuals respond better than others to the cholesterol lowering effects of both statin drugs and plant sterol functional foods, and this has been linked to particular genotypes (Schmitz and Langmann, 2006) .
Unlike pharmacological interventions in which drug access, is tightly controlled, nutritional intervention with functional foods is generally unrestricted in terms of access and professional advice may not be involved. However, in both approaches, individuals have total control over whether to take the food/drug or not, and such decisions in the future will be based on knowledge of the genotype.
Genomics tools used by both approaches
In order to implement personalized nutrition and pharmacology approaches, it is critical that the individuals be genotyped. The current data indicate that approximately 30 000 genes are in the human genome (Guttmacher and Collins, 2002) . Only about half of 30 000 genes, have recognizable DNA sequence patterns that suggest possible functions. Mutations known to cause disease have been identified in approximately 1000 genes although many more SNPs have been detected. However, it is likely that nearly all human genes are capable of causing disease if they are altered substantially. Owing to the dynamic nature of DNA expression and also through the mechanism of alternative splicing, more than 100 000 proteins can be derived from these B30 000 genes. In addition, a number of 'epigenetic' phenomena, such as methylation and histone modification, can alter the effect of a gene (Feinberg, 2001; Verma et al., 2003) . Maternal nutritional status, in particular, can alter the epigenetic state of the fetal genome and resultant subtle phenotypic differences observed in identical twins (Dennis, 2003) .
The commonest type of genetic variability is the SNP, a single base substitution within the DNA sequence (Chakravarty, 2001) , although other structural genetic changes also occur (Feuk et al., 2006) . These SNPs occur roughly once every 1000-2000 nucleotides in the human genome. Research indicates that, just as SNPs are associated with responsiveness to pharmaceuticals, they may also influence the responsiveness of individuals to changes in nutrient intake. For example SNPs may be responsible for variations in the lipeamic response to dietary lipids (Minihane et al., 2000) , influence the interrelationship between plasma vitamin B 12 , folate and homocysteine (Andreassi et al., 2003) and modulate the ability of fish oil to reduce production of the proinflammatory cytokine tumor necrosis factor (TNF) . Recent development of extensive genetic polymorphism databases and high throughput genetic screening now make meaningful study of inter-individual variation not only possible but also critical for the future of nutrition and clinical research. SNPs may be screened using a range of technologies. However, microarray chips, with the ability to screen for huge numbers of SNPs simultaneously, have the potential to revolutionize population and individual genotyping along with the development of hapmaps (International Hapmap consortium) (Gabriel et al., 2002; Lin et al., 2005) , which allow efficient mapping of associated SNPs not in linkage disequilibrium.
Other technologies are being developed that will also be of major significance for both pharmacogenomics and nutrigenomics. These allow the simultaneous determination of the expression of many thousands of genes at the mRNA (transcriptomics) (Gail, 2005) and protein (proteomics) (Nebert and Vesell, 2004) level, as well as the determination of the majority of the cellular metabolites (metabolomics) (German et al., 2003) . Not only is genotyping of importance in determining variation in response, but other 'phenotypic' approaches are critical in detecting differences in genetically based responses to drugs and food.
One thing is clear; pharmacogenomics will be the driver for application of genomics technologies to pharmacology, and nutrigenomics will piggyback on the advances made by medicine. This is because of the expense and technical demands of genotyping and related disciplines. Pharmaceutical companies will be driven to genotype populations in order to minimize risk and avoid inappropriate or ineffective drug based therapies, and medical personnel will subsequently genotype their patients in order to take advantage of knowledge of gene/drug interactions. Few will be genotyped solely to maintain or improve their health through good nutrition. However, because the individual genotype information will be available through pharmacogenomics, this knowledge could be applied in developing individualized nutrition or nutrigenomics.
Ethical, legal and social implications of nutrigenomics and pharmacogenomics
The ethical, legal and social implications arising from advances in genomic research have been well recognized and have strong implications for both pharmacogenomics and nutrigenomics (Kaput et al., 2005; Bergmann et al., 2006) . Major issues are privacy and fairness in the use and interpretation of genetic information, clinical integration of new genetic technologies, issues surrounding genetic research and public and professional education (http:// www.genome.gov/10001754#what). Disclosure of genetic information to others, intentional or otherwise, may be followed by social stigmatization and discriminatory practices by employers, insurers or schools. Patenting and licensing issues related to human genes add to the complexity and conceivably the expense of genetic testing (Guttmacher and Collins, 2002) . Disparity in access to genomic medicine in economically poor regions of the world must also be addressed. Genetic literacy among health care providers is also an important issue. Accurate original research, interpretation of patient genotype and application of the integrated information is critical to avoiding errors and could have far-reaching legal implications in medical malpractice. Again, nutrigenomics is likely to follow the lead of pharmacogenomics in this regard, with emphasis on patient-doctor confidentiality, and the use of professional advice in medical as well as nutritional decision-making by the individual. Although companies may offer services in genotyping, it is likely that implementation of genotypic advice will be on an individual basis for both disciplines. It is also likely that both disciplines will have an impact on drug and food labelling, although it may be some time before a food is labelled with a statement indicating the genotypes it is aimed at.
From the negative viewpoint, the new sciences of 'nutrigenomics' and the idea of 'personalised nutrition' have been challenged recently (e.g. GeneWatch, 2006) . The challenge advocated that, in most cases, genetic differences appear to make only small and subtle differences to a person's risk of diet-related disease and hence very little difference to the foods they should eat. We do not believe this is borne out by the information and examples presented in this review.
Conclusions and expectations of the future
Individual genetic variation is the common factor on which both pharmacogenomics and nutrigenomics are based. One of the expectations of both technologies is that a wide range of modified genes and related SNPs will be identified, validated and incorporated into strategies for the optimization of health and the prevention of disease through drugs and nutrition. This will introduce a massive set of new data and increase the biological complexity of developing drugs and food-based dietary guidelines that will shape the future of medicine and health. Pharmacogenomics requires rigorous genomic testing that will be regulated and analyzed by professionals and acted on by medical practitioners. As recognition grows of the importance of food in disease prevention and health, pharmacogenomics can provide an opportunity driver for nutrigenomics. In addition, as our understanding of the action of a wide range of animal, plant and microbial nutrients develops, we may find that the continuum from pharmaceuticals to nutraceuticals through to food-based bioactive compounds (often secondary plant products which may be pharmaceuticals in their own right) will bring the disciplines of pharmacogenomics and nutrigenomics closer together. Likewise, as we move from disease treatment to disease prevention, the two disciplines may be more closely aligned.
In the light of the new era of pharmacogenomics and nutrigenomics, policymakers and regulators can expect to wrestle with the complex issue of subpopulations as the simplicity of 'one-size-fits-all' erodes in the full light of new knowledge. Similarly, the drug and food industries may expect to encounter challenging new business demands as mass-marketing moves toward mass-customization. Finally, as society moves to adopt these practices, it may see a bioethical debate ensue over the impact of a growing 'genomic divide' in personal and global health equity (Editorial, 2001; Gillies, 2003; Guttmacher and Collins, 2003; William et al., 2004) .
The future for both disciplines looks bright, and as new knowledge is obtained, the quote from Jean Anthelme Brillat-Savarin (1755 -1826 'tell me what you eat, and I will tell you what you are' will need to become 'tell me what you eat, what drugs you take, and your genotype, and I will tell you what you are'!
